Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.

Hermiller, James B

Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. [electronic resource] - Journal of interventional cardiology Dec 2012 - 565-75 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1540-8183

10.1111/j.1540-8183.2012.00766.x doi


Angioplasty, Balloon, Coronary
Cardiovascular Agents--administration & dosage
Coronary Artery Disease--therapy
Drug-Eluting Stents
Everolimus
Female
Humans
Male
Middle Aged
Myocardial Infarction--epidemiology
Prospective Studies
Sirolimus--administration & dosage
Thrombosis--epidemiology
United States--epidemiology